98
The idea of operating breast cancer first and then administering therapy “blindly” is fading. Or, better: in the era of precision medicine, in which all treatments and their sequence are (or should be) established on the basis of the molecular characteristics of the tumor and the possible presence of certain mutations in the woman, a further step forward.